08156.HK
Sinopharm Tech Holdings Limited
HKSE · Technology · Software - Application · HK
HKD 0.17
+7.69%Year over year
Reported trailing growth
- Revenue
- +60.7%
- EBITDA
- -38.5%
- EBIT
- +38.4%
- EPS
- +106.1%
- Free cash flow
- +78.0%
- Operating cash flow
- +46.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +14.3%
- EBITDA
- +22.7%
- EBIT
- +22.2%
- Net income
- +95.6%
- EPS
- +98.3%
- Free cash flow
- +42.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025